Product Name:

MARK1-ANT


Product Number:

ab-nk092-2

Price:

Regular price
$89.00
Regular price
Sale price
$89.00

Download Product PDF

Target Full Name: MAP/microtubule affinity-regulating protein-serine kinase 1

Target Alias: KIAA1477; MAP/microtubule affinity-regulating kinase 1; MARK

Product Type Specific: Protein kinase pan-specific antibody

Antibody Code: NK098-2

Antibody Target Type: Pan-specific

Protein UniProt: Q9P0L2

Protein SigNET: Q9P0L2

Antibody Type: Polyclonal

Antibody Host Species: Rabbit

Antibody Immunogen Source: Human MARK1 sequence peptide Cat. No.: PE-01BDQ90

Antibody Immunogen Sequence: YTEPHIQPTKSSSRQNIPRC

Antibody Immunogen Description: Corresponds to amino acid residues Y24 to C43; Post-N-terminus

Production Method: Corresponds to amino acid residues Y24 to C43; Post-N-terminus

Antibody Modification: Protein kinase pan-specific antibody

Antibody Concentration: 0.5 mg/ml

Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol

Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.

Product Use: Western blotting | Antibody microarray

Antibody Dilution Recommended: 2 µg/ml for immunoblotting

Antibody Species Reactivity: Human

Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 85-90 kDa.

Scientific Background: MARK1 is a protein-serine/threonine kinase that is is a member of the CAMK group of protein kinases in the CAMKL family, and MARK subfamily. It mediates control of cell polarity and microtubule function. This kinase is highly expressed and widely distributed in most tested human tissues except apparently in the brain and spinal cord. It is activated by phosphorylation on T215 by STK11 in complex with STE20-related adapter-alpha (STRAD alpha) pseudo kinase and CAB39. MARK1 phosphorylates microtubule-associated proteins and trigger microtubule disruption. Gene mutation studies performed in mice revealed that after targeted disruption of the MARK1 gene, the mice lacked the ability to drink, and displayed hind leg motor dysfunction. Genetic variations in MARK1 have been correlated with susceptibility to autism. MARK1 is over-expressed in the prefrontal cortex of autism patients and affects the function of cortical dendrites. MARK1 has also been linked with the development of gastric adenocarcinomas and ovarian serous carcinomas.